QYUNS THERAPEUTICS
Qyuns is developing six candidates, most of them interleukin antibodies. It has two biosimilar drugs in China clinical trials, including a biosimilar to tocilizumab, a Chugai drug marketed as Actemra for various rheumatoid arthritis conditions.
QYUNS THERAPEUTICS
Industry:
Health Care Therapeutics
Founded:
2015-01-01
Address:
Taizhou, Jiangsu, China
Country:
China
Website Url:
http://www.qyuns.net
Total Employee:
51+
Status:
Active
Total Funding:
35.82 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Mobile Non Scaleable Content Euro ASP.NET IIS Pound Sterling Japanese Yen IIS 7
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Lysosomal Therapeutics
Lysosomal Therapeutics deliver cures for neurodegenerative diseases.
Pandion Therapeutics
Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Current Employees Featured
Founder
Investors List
Shenzhen Kaiding Juncan venture Cci Capital
Shenzhen Kaiding Juncan venture Cci Capital investment in Series C - Qyuns Therapeutics
TriWise Capital
TriWise Capital investment in Series C - Qyuns Therapeutics
Jiayin Investment
Jiayin Investment investment in Series B - Qyuns Therapeutics
Lucky Source Funds
Lucky Source Funds investment in Series B - Qyuns Therapeutics
TriWise Capital
TriWise Capital investment in Series B - Qyuns Therapeutics
Hongtai Capital Holdings
Hongtai Capital Holdings investment in Series B - Qyuns Therapeutics
Hefu Ruitai
Hefu Ruitai investment in Series B - Qyuns Therapeutics
Official Site Inspections
http://www.qyuns.net Semrush global rank: 8.76 M Semrush visits lastest month: 261
- Host name: 120.78.166.66
- IP address: 120.78.166.66
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Qyuns Therapeutics"
qyuns.net - 荃信生物
荃信生物（2509.HK）成立于2015年，是一家专注于自身免疫及过敏性疾病生物疗法的临床后期阶段生物医药企业，拥有完全自主研发的药物管线及成熟的商业级规模的内部生产能力。荃信生 …See details»
Qyuns Therapeutics Co., Ltd.
Adhering to the vision of "innovation for the great majority", Qyuns Therapeutics (2509.HK)，as a high-tech enterprise focuses on R&D, industrialization and commercialization of antibody …See details»
Qyuns Therapeutics - Crunchbase Company Profile
Qyuns is developing six candidates, most of them interleukin antibodies. It has two biosimilar drugs in China clinical trials, including a biosimilar to …See details»
Organization: Qyuns Therapeutics - Cbonds.com
Profile Qyuns Therapeutics Co Ltd is a China-based company mainly engaged in biopharmaceuticals. The Company is mainly engaged in biotechnology research and …See details»
QYuns Therapeutics - VentureRadar
"Qyuns Therapeutics is a biopharmaceutical company focus on the development of high-quality antibody drugs for the treatment of autoimmune disease. Our mission is to develop high …See details»
Qyuns Therapeutics Co., Ltd. - Drug pipelines, Patents, Clinical …
Apr 8, 2025 Explore Qyuns Therapeutics Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 33 clinical trials, 1 news, and 3 literature, Disease Domain ...See details»
Qyuns Therapeutics Co., Ltd.
Qyuns Successfully Listed on the Main Board of SEHK Entered into a collaboration agreement with Joincare Pharmaceutical Group Industry Co., Ltd. (“Joincare”) with respect to the …See details»
Qyuns 2025 Company Profile: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Qyuns. Use the PitchBook Platform to explore the full profile.See details»
Qyuns Therapeutics - Overview, News & Similar companies
View Qyuns Therapeutics (www.qyuns.net) location in Jiangsu, China , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Qyuns Therapeutics Co., Ltd. - cnverify.com
1.Company information What is the email and phone number of Qyuns Therapeutics Co., Ltd.? What year was Qyuns Therapeutics Co., Ltd. started?See details»
Qyuns Therapeutics Co., Ltd. (HKG:2509) Company Profile
Feb 14, 2025 Company profile for Qyuns Therapeutics Co., Ltd. (HKG:2509) with a description, list of executives, contact details and other key facts.See details»
QYuns Therapeutics Signs Global Licensing Deal with Caldera for ...
Apr 24, 2025 Additionally, QYuns is eligible for milestone payments totaling up to USD 545 million, tied to clinical development, regulatory achievements, and commercial milestones, …See details»
Qyuns Therapeutics Announces Board Structure and Roles
Oct 25, 2024 Qyuns Therapeutics Co., Ltd., a joint stock company in China, has announced the list of its board of directors and their respective roles. The board includes executive, non …See details»
Qyuns Therapeutics Co., Ltd. (江苏荃信生物医药股份有限公司) - 药 …
了解Qyuns Therapeutics Co., Ltd. (江苏荃信生物医药股份有限公司)公司的药物管线，治疗领域，技术平台，以及它的33项临床试验, 1篇新闻和3篇文献，疾病领域:免疫系统疾病，感染，肿 …See details»
Qyuns Therapeutics Co., Ltd.
We are a clinical-stage biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline and an established …See details»
Hansoh Pharma and Qyuns Announce Licensing Agreement and …
Apr 25, 2024 Pursuant to the Licensing Agreement, Hansoh Pharma has obtained an exclusive license from Qyuns to develop and commercialize QX004N within China (including Hong …See details»
荃信生物_医疗项目_动脉网数据 - vbdata.cn
目前，荃信生物已拥有及申报国内外专利70余项，为国家级高新技术企业，亦被江苏省生产力促进中心认定为潜在独角兽企业。 13092200188 [email protected] 51~100人 泰州市药城大 …See details»
Qyuns Therapeutics Co., Ltd.
Effective status, as we can utilize the completed Phase I test resultsQyuns Therapeutics Co., Ltd.See details»
Qyuns Therapeutics Co., Ltd.
With respect to the commercialization of certain drug candidates, in particular, drug candidates indicated for diseases with patients located in vast, geographically dispersed areas,we plan to …See details»
Qyuns Therapeutics Co., Ltd.
Qyuns is developing a series of antibody drugs targeting autoimmune and allergic diseases. We are willing to collaborate with potential partners who plans to set foot in the field of …See details»